Pfizer (PFE) Other financing activities (2009 - 2026)

Pfizer (PFE) has 18 years of Other financing activities data on file, last reported at -$284.0 million in Q1 2026.

• Quarterly Other financing activities rose 20.22% year-over-year to -$284.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$386.0 million (up 69.37% YoY) and the FY2025 annual result came in at -$458.0 million, up 2.35% from the prior year.
• Other financing activities declined to -$284.0 million in Q1 2026 per PFE's latest filing, from -$43.0 million in the prior quarter.
• Across five years, Other financing activities topped out at $154.0 million in Q3 2022 and bottomed at -$501.0 million in Q2 2022.
• The 5-year median for Other financing activities is -$140.0 million (2023), against an average of -$197.7 million.
• The widest annual swing landed in 2024, when Other financing activities sank 1129.73%; it then soared 91.65% in 2025.
• Tracing PFE's Other financing activities over 5 years: stood at -$342.0 million in 2022, then soared by 94.74% to -$18.0 million in 2023, then sank by 2427.78% to -$455.0 million in 2024, then surged by 90.55% to -$43.0 million in 2025, then sank by 560.47% to -$284.0 million in 2026.
• Per Business Quant, the three latest PFE Other financing activities figures stand at -$284.0 million (Q1 2026), -$43.0 million (Q4 2025), and -$38.0 million (Q3 2025).

Peer Comparison